Ping An Biomedical Co., Ltd. filed a Form 6-K on November 17, 2026, reporting that it received formal notification from Nasdaq on November 16, 2026, that it has regained compliance with the Nasdaq Minimum Bid Price Requirement under Listing Rule 5550(a)(2).

Key Highlights

  • Compliance restored: Nasdaq notified the company on November 16, 2026, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
  • Qualifying period: The closing bid price of the company's ordinary shares was at $1.00 per share or greater for 10 consecutive business days from November 2, 2026 to November 13, 2026.
  • Matter closed: According to the filing, "Nasdaq considers the prior bid price deficiency matter now closed."
  • Original deficiency: The company first received a noncompliance notice from Nasdaq on November 24, 2025, after the bid price closed below $1.00 per share for 30 consecutive business days.
  • Extension granted: On May 26, 2026, Nasdaq granted the company an additional 180 calendar day period, until November 23, 2026, to regain compliance.

Ping An Biomedical's Path Back to Nasdaq Bid Price Compliance

According to the Form 6-K filed with the SEC, Ping An Biomedical Co., Ltd. (NASDAQ:PASW) disclosed that it received formal written notification from Nasdaq on November 16, 2026, confirming that it had regained compliance with the minimum bid price requirement. Nasdaq's determination followed the company's ordinary shares closing at $1.00 per share or greater for 10 consecutive business days, specifically the period from November 2, 2026 to November 13, 2026, satisfying the threshold set out under Listing Rule 5550(a)(2).

The filing recounts that the noncompliance process began on November 24, 2025, when Nasdaq notified the company that its bid price had closed below $1.00 per share for 30 consecutive business days. The company was subsequently granted an initial compliance period, followed by a second 180-calendar-day extension communicated by Nasdaq on May 26, 2026, setting a deadline of November 23, 2026. The filing notes that Nasdaq's extension was based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable initial listing requirements for the Capital Market, except for the bid price requirement. At the time of the extension, the company also provided written notice of its intention to cure the deficiency, including by effecting a reverse stock split if necessary.

With the compliance confirmation received before the November 23, 2026 deadline, the company did not need to implement a reverse stock split. The filing, signed by Pijun Liu, Chairperson of the Board of Directors, states that Nasdaq considers the prior bid price deficiency matter now closed.

What Was Disclosed

Ping An Biomedical Co., Ltd. reported in a Form 6-K that Nasdaq formally confirmed on November 16, 2026, that the company has regained compliance with the minimum bid price listing rule, closing a deficiency matter that began in November 2025.